Immunotherapies that target PD-1/PD-L1 checkpoints of the immune system confirmed effective results in the therapy of hepatic cell carcinoma (HCC); however, its monotherapy is limited to a small section of HCC patients. Here, CD274 is linked to hepatocellular carcinoma.